Close-up CRM

Overview

Close-up CRM is best read as a pharma commercial-technology and market-data vendor, not as a classic outsourced field-force provider. The company combines prescription and sales analytics, CRM workflows, HCP targeting, activity reporting, and market access business intelligence for manufacturer commercial teams. Its strongest differentiation is the combination of proprietary market data and CRM execution in one workflow, particularly in Latin America where Close-Up has long-standing prescription-audit heritage; the MobileDotRep acquisition is the U.S. diligence hook for buyers testing domestic references.

The public buyer question is whether Close-up can replace or complement the manufacturer’s existing Veeva, Salesforce, IQVIA, and local-market data stack. For U.S. teams, the MobileDotRep acquisition and market access BI announcements create a credible reason to include Close-up in early diligence, but buyers should validate actual U.S. references, integration depth, data rights, and support model before treating it as a full enterprise CRM alternative.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Close-up CRM is evaluated as a pharma commercial-technology and market-data vendor, not as a classic outsourced field-force provider.

Capability	Buyer should compare	Close-up CRM readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Core in commercial data. The central promise is bringing prescription and sales-market data into commercial CRM workflows. Validate geography, source rights, update cadence, and downstream export rights.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Core. Close-up is strongest where HCP targeting and commercial execution depend on local prescription / sales data.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Core. CRM is a primary product lane; buyers should compare fit against Veeva Vault CRM, Salesforce Life Sciences Cloud, and retained local CRM tools.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Documented adjacency. Market access BI is part of the public positioning, but payer / pharmacy network depth should be validated by market.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Validate in RFP. Public positioning uses AI language, but buyers should ask for specific production use cases, controls, and measurable adoption.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Critical diligence point. Cross-border data rights and commercial-data handling matter more than generic security claims.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Core / validate scope. Reporting and BI are central to the pitch; confirm whether outputs can feed the manufacturer’s CRM, data lake, hub, and market access analytics stack.

Buyer Fit

• Best shortlist motion: Include Close-up when the manufacturer wants commercial CRM tightly tied to prescription / sales analytics, especially for Latin America or markets where local data coverage is the buying driver.
• Best-fit buyer: Pharma and biotech commercial teams evaluating HCP targeting, CRM activity capture, launch analytics, market access BI, or U.S. expansion alternatives after the MobileDotRep acquisition.
• Less ideal fit: Manufacturers seeking an enterprise-wide regulated platform across content, medical, R&D, quality, safety, and global CRM standardization should compare Veeva and Salesforce first.
• Commercial model: Subscription-led platform sale with implementation, integrations, training, and data scope likely defined through an RFP.
• Operating risk: Treat U.S. proof points separately from Latin America proof points. The capabilities may be real, but buyer diligence should confirm local references and data availability in the exact market being launched.

Differentiators

• Data-plus-CRM model: Close-up’s pitch is not just activity capture; it is commercial execution informed by prescription and sales-market data.
• Latin America data heritage: The company traces its prescription-audit roots to 1968, which matters in markets where local prescription / sales data coverage is a primary need.
• U.S. expansion option: The MobileDotRep acquisition gives Close-up a more direct U.S. CRM wedge, but traction and enterprise reference depth should be tested.
• Market access BI adjacency: The VS Health Group announcement supports a market access BI use case beyond standard rep activity logging.
• Middle-market alternative posture: Close-up may be attractive where a team needs a pharma-specific CRM/data stack without adopting the full cost or complexity of a Veeva or Salesforce enterprise program.

RFP Questions

• Which countries, channels, and data sources are covered, and what source rights are included in the contract?
• How does Close-up coexist with or replace Veeva, Salesforce, IQVIA data feeds, Snowflake, and existing BI environments?
• What production references exist for the exact geography, therapy area, and launch stage being evaluated?
• What came with MobileDotRep, and which U.S. CRM features are live today versus roadmap?
• How are data privacy, audit logs, consent, field permissions, model governance, and cross-border data handling managed?
• Which market access BI workflows are native, and which require custom configuration or services?

Recent Activity

• October 2025: Close-Up International was selected by VS Health Group to deliver a market access business-intelligence CRM solution.
• September 2025: Close-Up International acquired MobileDotRep, expanding its U.S. commercial CRM footprint.
• 2025: Public materials continued to position Close-up around integrated CRM, prescription / sales analytics, and commercial effectiveness.